Where Will Marker Therapeutics Inc (MRKR) Stock Go Next After It Has Risen 18.18% in a Week?

Overall market sentiment has been high on Marker Therapeutics Inc (MRKR) stock lately. MRKR receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.

Marker Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on MRKR!

See Full MRKR Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With MRKR Stock Today?

Marker Therapeutics Inc (MRKR) stock has risen 6.23% while the S&P 500 has fallen -0.11% as of 1:35 PM on Friday, Mar 25. MRKR has gained $0.03 from the previous closing price of $0.48 on volume of 1,143,408 shares. Over the past year the S&P 500 is up 16.10% while MRKR has fallen -77.68%. MRKR lost -$0.55 per share in the over the last 12 months. To screen for more stocks like Marker Therapeutics Inc click here.

More About Marker Therapeutics Inc

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart. Click Here to get the full Stock Report for Marker Therapeutics Inc stock.